Heidelberg Pharma AG (XTER:HPHA) PB Ratio: (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:HPHA Heidelberg Pharma AG XTER:HPHA
32 GF Score
Price €2.55
GF Value €2.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), Heidelberg Pharma AG's share price is €2.55. Heidelberg Pharma AG's Book Value per Share for the quarter that ended in May. 2026 was €-0.30. Hence, Heidelberg Pharma AG's PB Ratio of today is .

The historical rank and industry rank for Heidelberg Pharma AG's PB Ratio or its related term are showing as below:

During the past 13 years, Heidelberg Pharma AG's highest PB Ratio was 37.00. The lowest was 1.39. And the median was 3.60.

XTER:HPHA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.93
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Heidelberg Pharma AG's average Book Value Per Share Growth Rate was -160.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Heidelberg Pharma AG was 50.00% per year. The lowest was -60.00% per year. And the median was -4.55% per year.

Back to Basics: PB Ratio


Heidelberg Pharma AG  (XTER:HPHA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Heidelberg Pharma AG PB Ratio Related Terms


Heidelberg Pharma AG PB Ratio Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG PB Ratio Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.43 4.00 2.61 3.63 0.00

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.51 16.31 0.00 0.00 0.00

XTER:HPHA vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, Heidelberg Pharma AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's PB Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's PB Ratio falls into.


XTER:HPHA
32GF Score
Heidelberg Pharma AG XTER:HPHA
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Heidelberg Pharma AG's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: May. 2026)
=2.55/-0.304
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for XTER:HPHA:

  • PB Ratio:
  • GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score

Get the complete analysis for XTER:HPHA

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.87
GF Value